Immunogenic and immunotolerogenic effects of extracorporeal photopheresis in high immunological risk kidney recipients. A single center case series

J Clin Apher. 2022 Jun;37(3):197-205. doi: 10.1002/jca.21958. Epub 2021 Dec 22.

Abstract

The immunomodulatory effects of extracorporeal photopheresis (ECP) have been used for the treatment of T-cell mediated disorders, such as rejection in organ transplantation. Currently, it is an established therapy for heart and lung rejection, but not for kidney transplantation (KT), where experience is limited. In addition, some data suggest that ECP could generate an immune response against infections, thus being an alternative for the treatment of rejection in case of active or high-risk of infection. In the present study, we analyze four cases of use of ECP as concomitant therapy in patients with KT and high risk of opportunistic infections due to the high burden of immunosuppression throughout their renal diseases. Two patients had concomitant viral infection (cytomegalovirus and BK virus, respectively) and three patients were on treatment for graft rejection. In the two patients with active viral infection, the infection was successfully controlled during ECP treatment. In all cases, ECP has been shown to be a safe procedure, without complications.

Keywords: extracorporeal photopheresis; infection; kidney transplant; rejection.

MeSH terms

  • Graft Rejection / therapy
  • Humans
  • Immunosuppression Therapy / adverse effects
  • Kidney
  • Kidney Transplantation* / adverse effects
  • Photopheresis* / methods